---
title: "MACMIC released its semi-annual performance, with a net profit attributable to the parent company of 2.98 million yuan, a year-on-year increase of 18.45%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255055625.md"
description: "According to the Zhitong Finance APP, MACMIC disclosed its semi-annual report for 2025, reporting revenue of 680 million yuan, a year-on-year increase of 6.86%; net profit attributable to the parent company of 2.98 million yuan, a year-on-year increase of 18.45%; a net profit loss of 180,000 yuan after deducting non-recurring items; and basic earnings per share of 0.0140 yuan"
datetime: "2025-08-28T16:03:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255055625.md)
  - [en](https://longbridge.com/en/news/255055625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255055625.md)
---

# MACMIC released its semi-annual performance, with a net profit attributable to the parent company of 2.98 million yuan, a year-on-year increase of 18.45%

According to the Zhitong Finance APP, MACMIC (688711.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 680 million yuan, a year-on-year increase of 6.86%; net profit attributable to shareholders was 2.98 million yuan, a year-on-year increase of 18.45%; net profit excluding non-recurring items was a loss of 180,000 yuan; basic earnings per share were 0.0140 yuan

### Related Stocks

- [688711.CN](https://longbridge.com/en/quote/688711.CN.md)

## Related News & Research

- [Just 4% of fund managers see a hard landing - BofA survey](https://longbridge.com/en/news/286866256.md)
- [Hunter: Inflation expectations drifting higher is an elevated risk RBA cannot ignore](https://longbridge.com/en/news/286828731.md)
- [What are the main events for today?](https://longbridge.com/en/news/286864609.md)
- [PharmEasy's parent has a new playbook: Profit first, growth second](https://longbridge.com/en/news/286890424.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)